-2%
- Hydroxyurea is metabolized into nitroxide (NO), which inhibits ribonucleotide reductase by targeting its tyrosyl radical.
- This action suppresses DNA synthesis, selectively killing cells in the S phase of the cell cycle.
- Hydroxyurea also:
- Interferes with DNA repair after radiation/chemical damage.
- Increases fetal hemoglobin levels via NO-mediated activation of soluble guanylyl cyclase, reducing sickle cell crises.
Hydronix is indicated for the treatment of various conditions, including:
Cancers:
- Melanoma
- Resistant chronic myeloid leukemia (CML)
- Recurrent metastatic or inoperable ovarian carcinoma
- Primary squamous cell carcinomas of the head and neck (excluding lip) when used with radiation therapy
- Carcinoma of the cervix
Hematological Disorders:
- β-thalassemia: Reduces painful crises and blood transfusion needs.
- Essential thrombocythemia and polycythemia vera: Helps manage platelet counts and blood consistency.
- Sickle cell anemia: Decreases the frequency of painful crises and the need for transfusions.